Abdel-Rahman O - Search Results

1

Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting.

Sam D, Gresham G, Abdel-Rahman O, Cheung WY. Sam D, et al. Med Oncol. 2018 Jun 18;35(7):110. doi: 10.1007/s12032-018-1167-7. Med Oncol. 2018. PMID: 29915956 Clinical Trial.

2

Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.

Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Abdel-Rahman O, et al. Med Oncol. 2013;30(3):655. doi: 10.1007/s12032-013-0655-z. Epub 2013 Jul 4. Med Oncol. 2013. PMID: 23824645 Clinical Trial.

3

Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Expert Rev Anticancer Ther. 2015 Feb;15(2):165-82. doi: 10.1586/14737140.2015.978295. Epub 2014 Nov 3. Expert Rev Anticancer Ther. 2015. PMID: 25363192 Review.

4

Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2014 Oct;10(12):1981-92. doi: 10.2217/fon.14.42. Future Oncol. 2014. PMID: 25386814 Review.

5

Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials.

Abdel-Rahman O. Abdel-Rahman O. Med Oncol. 2015 Jan;32(1):431. doi: 10.1007/s12032-014-0431-8. Epub 2014 Dec 9. Med Oncol. 2015. PMID: 25487446 Review.

6

Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(1):79-90. doi: 10.2217/fon.14.136. Future Oncol. 2015. PMID: 25572784

7

Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.

Abdel-Rahman O, Elhalawani H. Abdel-Rahman O, et al. Future Oncol. 2015;11(7):1109-22. doi: 10.2217/fon.15.16. Future Oncol. 2015. PMID: 25804125

8

Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(8):1275-90. doi: 10.2217/fon.14.302. Future Oncol. 2015. PMID: 25832882 Review.

9

Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(12):1829-43. doi: 10.2217/fon.15.33. Future Oncol. 2015. PMID: 26075449 Review.

10

Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.

Abdel-Rahman O, ElHalawani H, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(17):2471-84. doi: 10.2217/fon.15.118. Epub 2015 Aug 14. Future Oncol. 2015. PMID: 26274495 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

347 results

Search Page

Filters